These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 26684240

  • 1. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C, Ha SY, Kim ST, Kim HC, Heo JS, Park YS, Lauwers G, Lee J, Kim KM.
    Oncotarget; 2016 Jan 26; 7(4):4024-35. PubMed ID: 26684240
    [Abstract] [Full Text] [Related]

  • 2. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.
    Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.
    Int J Cancer; 2019 Mar 15; 144(6):1379-1390. PubMed ID: 30144031
    [Abstract] [Full Text] [Related]

  • 3. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS, Chen M, Kim JH, Kim WH, Ahn S, Maeng K, Allegra CJ, Kaye FJ, Hochwald SN, Zajac-Kaye M.
    Int J Cancer; 2014 Jul 01; 135(1):128-37. PubMed ID: 24347111
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A, Poorman K, Salem ME, Soldato D, Seeber A, Goldberg RM, Shields AF, Xiu J, Battaglin F, Berger MD, Tokunaga R, Naseem M, Barzi A, Iqbal S, Zhang W, Soni S, Hwang JJ, Philip PA, Sciallero S, Korn WM, Marshall JL, Lenz HJ.
    Clin Cancer Res; 2020 Nov 15; 26(22):5943-5951. PubMed ID: 32883742
    [Abstract] [Full Text] [Related]

  • 5. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M, Čačev T, Catela Ivković T, Marout J, Ulamec M, Zjačić-Rotkvić V, Kapitanović S.
    Mol Cell Endocrinol; 2016 Apr 15; 425():61-8. PubMed ID: 26805636
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, Lothe IMB, Sorbye H.
    J Neuroendocrinol; 2023 Apr 15; 35(4):e13256. PubMed ID: 37017614
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.
    Ahn HK, Choi JY, Kim KM, Kim H, Choi SH, Park SH, Park JO, Lim HY, Kang WK, Lee J, Park YS.
    Br J Cancer; 2013 Sep 17; 109(6):1414-9. PubMed ID: 23989950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S, Norlén O, Eriksson B, Skogseid B, Stålberg P, Crona J.
    Anticancer Res; 2017 Feb 17; 37(2):705-712. PubMed ID: 28179320
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C, Zheng Q, Yang Y, Xu M, Lian Y, Huang J, Jiang Y.
    Appl Immunohistochem Mol Morphol; 2019 Sep 17; 27(8):599-605. PubMed ID: 30095460
    [Abstract] [Full Text] [Related]

  • 14. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.
    Cancer Discov; 2016 Jun 17; 6(6):594-600. PubMed ID: 27048246
    [Abstract] [Full Text] [Related]

  • 15. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A, Scognamiglio G, Aquino G, Cerrone M, Liguori G, Clemente O, Di Bonito M, Cantile M, Botti G, Tafuto S, Tatangelo F.
    Int J Mol Sci; 2021 Jun 30; 22(13):. PubMed ID: 34208964
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S, Akita M, Fujikura K, Komatsu M, Sawada R, Matsumoto H, Saegusa J, Itoh T, Kakeji Y, Zen Y.
    Hum Pathol; 2021 Apr 30; 110():1-10. PubMed ID: 33359239
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F, Sipos B, Fahl M, Clauditz TS, Amin T, Kriegs M, Nieser M, Izbicki JR, Huber S, Lohse AW, Schrader J.
    Cell Oncol (Dordr); 2022 Dec 30; 45(6):1401-1419. PubMed ID: 36269546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.